Sanofi launches Probi Digestis® in Korea

2014-04-15

Sanofi launches Probi Digestis® in Korea

Probi has signed a distribution and supply agreement with Sanofi. Following this the Consumer Healthcare divison of Sanofi Korea is making a major launch of Probi´s gut health product, Probi Digestis® starting in April 2014. Probi has already delivered products and received substantial orders for the coming quarters.

Read the full release here

Probiotics from Probi can reduce the risk for osteoporosis

2014-04-11

New study shows that probiotics from Probi can reduce the risk for osteoporosis

Osteoporosis constitutes a major health concern that places a huge economic burden on the health care system and entails a lot of suffering for the patients. The increasing number of fractures associated with the increasing age of the population makes it of vast importance to develop alternatives for both prevention and treatment of the disease.

Read the full release here

Dr. Bengt Jeppsson’s article: “Help the aged”

2014-04-10

“Help the aged”

Dr. Bengt Jeppsson discusses the research into gut bacteria that could help to relieve the strain of the age-related illnesses which are increasingly impacting health services worldwide.

Read the full article here

Jeppsson, Bengt: ‘Help the aged’, International Innovation, Issue 134: Sustainable systems, March 2014, (Research Media, UK, pp 16-18) ISSN 2054-6254

Travel-friendly Probi Digestis® launched in Sweden

2014-04-10

Travel-friendly Probi Digestis® (Probi Mage®) launched in Sweden

A healthy digestive system is extra important when travelling overseas. Travel Pack makes it easier than ever to bring Probi Digestis® on your trip.

Read the full release here

Probi Mage to be launched in South Korea with Dongkook

2014-03-31

Probi Mage® to be launched in South Korea with Dongkook Pharmaceutical

Probi has signed a distribution agreement with Dongkook Pharmaceutical Co., Ltd., based in Seoul, South Korea for the distribution of Probi´s gut health product, Probi Mage®. The Product will be launched under Probi’s brand in South Korea in the second quarter of 2014.

Read the full release here

Annual General Meeting 2014

2014-03-27

The shareholders of Probi AB (publ) are hereby officially convened to the Annual General Meeting (AGM) which will be held on Tuesday 29 April 2014 at 3:00 p.m. at Elite Hotel, Ideon Gateway, Scheelevägen 27, Lund, Sweden. Intention to participate must be notified to the company no later than Wednesday, 23 April 2013 at 4:00 p.m. (CET).

Read the entire Notice of the Annual General Meeting 2014 here

Probi secures strategic US order

2014-03-21

Probi secures strategic US order

Probi has secured a major order valued at MSEK 3.6 from the US self-care product company Pharmavite. The order pertains to the dietary supplement Probi Digestis®, which promotes gastrointestinal health. The order is based on strong demand for Probi’s digestive health capsules in US pharmacies and retail stores. The order consisting of a number of part shipments will be delivered during the second and third quarter of 2014.

Read the full release here

 

Year-End Report 2013

2014-01-23

Consumer Healthcare up 24% in 2013

Read the full release here

Symrise has increased its shareholding in Probi to 30.03%, which gives rise to an obligation to launch a mandatory public offer

2014-01-13

Symrise has increased its shareholding in Probi to 30.03%, which gives rise to an obligation to launch a mandatory public offer

Probi has been informed that on 10 January 2014 Symrise AG (“Symrise”) acquired 11,010 shares in Probi AB (publ) (“Probi” or “the company”), which is listed on Nasdaq OMX Stockholm, whereby Symrise holds 2,812,505 Probi shares. Accordingly, Symrise’s shareholding in the company increased from about 29.91% of Probi’s share capital and voting rights to about 30.03% of the share capital and voting rights.

Read the full release here

New investments in Research and Regulatory

2013-11-26

New investments in Research and Regulatory

Probi continues to invest in research and development. During fall, a number of new clinical studies have started and work on defining Probi’s long term research focus has begun. As a part of this process, two strategically important posts have been filled to strengthen the organization.

Anna-Karin Robertson –  Head of Discovery
Efforts to develop a long-term R&D strategy include defining medium-term projects, but also more basic R&D work that may result in new products over the longer term. The post Head of Discovery is newly established with responsibility for working with Probi’s fundamental research initiatives. Anna-Karin specializes in inflammation and immunology, and holds a Ph.D. from the Department of Cardiovascular Research at the Center for Molecular Medicine, Karolinska Institutet. Her most recent position was as Principal Scientist at BioInvent International AB.

Anna-Lena Karlsson – Head of Regulatory Affairs
Anna-Lena Karlsson was engaged to manage the registration of Probi’s products in new markets.  She has extensive experience in Clinical Business Administration, Regulatory Affairs and Regulatory Intelligence, including from Astra Zeneca. Anna-Lena comes from a position as Senior Regulatory Affairs Manager at Mc Neil AB.